Subscribe

Immutep Limited (IMM.AX)

AUD0.06 +0.00 (+3.64%)
AU ASX Healthcare Biotechnology
Address Australia Square 2000
Sydney, NSW, AU
CEO Marc Voigt
Website immutep.com
IPO 1988-06-30
ISIN AU000000IMM6

Explore sections of this company profile

Also trades on Australian Securities Exchange · IMM.AX (AUD) NASDAQ Global Market · IMMP (USD) Other OTC · PRRUF (USD)
Description

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company’s product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
AUD0.06 +0.00 (+3.64%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
34M
Beta
2.24
Float Shares
1.26B
Free Float %
85.2%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+0.00% -10.17% -10.17% -86.23% -82.62% -87.23% -81.40% -81.07% -91.89% -87.57% -96.42%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Analyst Consensus (3 ratings, all time) Buy
Price Targets & DCF
Current price
0.06
DCF (Unlevered) 0.02 -66.3%
DCF (Levered) 0.00 -94.1%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 25% Bullish
Rating 2026-05 Change
Strong Buy 1 0
Buy 0 0
Hold 3 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
-5.87
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Biotechnology: +1.6%
    +31.3% ★ Q4'25: +93.3% (vs Q4'23)
  • ✗
    EPS growth Biotechnology: +29.7%
    -18.5% Q4'25: -70.4% (vs Q4'23)
  • ✗
    FCF margin FCF growth · Biotechnology: +16.2%
    -1,417.6% Q4'25: -704.4% (vs Q4'23)
  • ✗
    EBIT margin Biotechnology: +0.0%
    -1,288.9% Q4'25: -1,175.7% (vs Q4'23)
  • ✗
    ROIC Biotechnology: -16.1%
    -417.6% Q4'25: -9,950.1% (vs Q4'23)
  • ✗
    Share dilution Biotechnology: -3.4%
    +21.2% Q4'25: +24.0% (vs Q4'23)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×
    -0.03× Q4'25: -0.01× (vs Q4'23)
Valuation Multiples From To
DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (2.36) × ERP
WACC = 98% × Ke + 2% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 0.02 Current price: 0.06
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Jun 2010
actual 		Jun 2012
actual 		Jun 2014
actual 		Jun 2015
actual 		Jun 2016
actual 		Jun 2017
actual 		Jun 2018
actual 		Jun 2019
actual 		Jun 2020
actual 		Jun 2021
actual 		Jun 2022
actual 		Jun 2023
actual 		Jun 2024
actual 		Jun 2025
actual 		Jun 2026
6 Rev. Ana.
6 EPS Ana. 		Jun 2027
6 Rev. Ana.
6 EPS Ana. 		Jun 2028
5 Rev. Ana.
5 EPS Ana. 		Jun 2029
2 Rev. Ana.
1 EPS Ana. 		Jun 2030
2 Rev. Ana.
1 EPS Ana.
Revenue
523.7K
est: 125.86M (-99.6%)
1.52M
est: 1.50M (+1.2%)
2.43M
est: 1.77M (+37.1%)
1.87M
est: 1.43M (+31.0%)
175.1K
est: 2.49M (-93.0%)
4.12M
est: 5.18M (-20.5%)
2.63M
est: 8.08M (-67.5%)
139.8K
est: 7.85M (-98.2%)
7.49M
est: 13.05M (-42.6%)
3.86M
est: 5.49M (-29.6%)
170.4K
est: 2.54M (-93.3%)
3.51M
est: 5.69M (-38.4%)
3.84M
est: 4.29M (-10.5%)
5.04M
est: 8.15M (-38.1%)
26.73M
26.73M – 26.73M
+228.0% YoY
3.89M
3.89M – 3.89M
-85.5% YoY
4.22M
4.22M – 4.22M
+8.5% YoY
288.13M
288.13M – 288.13M
+6,729.8% YoY
907.37M
907.37M – 907.37M
+214.9% YoY
EBITDA
-7.82M
est: -125.86M (+93.8%)
-18.07M
est: -1.47M (-1,127.4%)
-14.41M
est: -1.74M (-730.4%)
-13.12M
est: -10.37M (-26.5%)
-60.63M
est: -57.28M (-5.8%)
-8.40M
est: -52.31M (+83.9%)
-10.51M
est: -45.16M (+76.7%)
-18.54M
est: -23.62M (+21.5%)
-13.94M
est: -24.62M (+43.4%)
-20.72M
est: -8.74M (-137.2%)
-31.87M
est: -18.24M (-74.8%)
-42.88M
est: -24.70M (-73.6%)
-44.54M
est: -40.03M (-11.3%)
-62.88M
est: -108.83M (+42.2%)
-26.73M
-26.73M – -26.73M
+75.4% YoY
-3.89M
-3.89M – -3.89M
+85.5% YoY
-4.22M
-4.22M – -4.22M
-8.5% YoY
-288.13M
-288.13M – -288.13M
-6,729.8% YoY
-907.37M
-907.37M – -907.37M
-214.9% YoY
EBIT
-7.89M
est: -125.86M (+93.7%)
-18.45M
est: -1.47M (-1,153.0%)
—
est: -1.74M (+100.0%)
—
est: -11.03M (+100.0%)
—
est: -16.53M (+100.0%)
—
est: -50.39M (+100.0%)
—
est: -38.91M (+100.0%)
-20.42M
est: -21.05M (+3.0%)
-16.02M
est: -25.88M (+38.1%)
-19.56M
est: -10.77M (-81.6%)
-33.94M
est: -22.48M (-51.0%)
-44.94M
est: -30.45M (-47.6%)
-46.56M
est: -49.35M (+5.7%)
-65.01M
est: -134.16M (+51.5%)
-26.73M
-26.73M – -26.73M
+80.1% YoY
-3.89M
-3.89M – -3.89M
+85.5% YoY
-4.22M
-4.22M – -4.22M
-8.5% YoY
-288.13M
-288.13M – -288.13M
-6,729.8% YoY
-907.37M
-907.37M – -907.37M
-214.9% YoY
Net Income
-12.16M
est: -292.02M (+95.8%)
-19.94M
est: -293.46M (+93.2%)
-13.34M
est: -146.73M (+90.9%)
-32.15M
est: -68.83M (+53.3%)
-62.02M
est: -36.74M (-68.8%)
-9.37M
est: -50.39M (+81.4%)
-12.75M
est: -38.96M (+67.3%)
-16.27M
est: -22.34M (+27.2%)
-13.47M
est: -25.25M (+46.7%)
-29.90M
est: -9.76M (-206.5%)
-32.21M
est: -20.36M (-58.2%)
-39.90M
est: -39.90M (+0.0%)
-42.72M
est: -42.72M (0.0%)
-61.43M
est: -61.43M (+0.0%)
-55.50M
-101.76M – -49.18M
+9.7% YoY
-52.04M
-92.26M – -10.38M
+6.2% YoY
-64.74M
-222.32M – -14.82M
-24.4% YoY
-28.77M
-28.77M – -28.77M
+55.6% YoY
67.61M
67.61M – 67.61M
+335.0% YoY
SGA
3.15M
est: 1.31B (-99.8%)
7.78M
est: 15.31M (-49.2%)
4.09M
est: 18.04M (-77.3%)
5.72M
est: 14.87M (-61.5%)
54.45M
est: 25.84M (+110.7%)
4.35M
est: 53.81M (-91.9%)
7.24M
est: 84.02M (-91.4%)
6.13M
est: 81.57M (-92.5%)
6.34M
est: 8.44M (-24.9%)
6.28M
est: 4.59M (+36.9%)
7.21M
est: 26.40M (-72.7%)
14.08M
est: 59.16M (-76.2%)
8.85M
est: 44.63M (-80.2%)
8.64M
est: 84.73M (-89.8%)
277.92M
277.92M – 277.92M
+228.0% YoY
40.44M
40.44M – 40.44M
-85.5% YoY
43.86M
43.86M – 43.86M
+8.5% YoY
3.00B
3.00B – 3.00B
+6,729.8% YoY
9.43B
9.43B – 9.43B
+214.9% YoY
EPS
-0.20
est: -0.20 (+0.3%)
-0.19
est: -0.20 (+5.3%)
-0.11
est: -0.10 (-9.7%)
-0.20
est: -0.09 (-129.4%)
-0.27
est: -0.04 (-589.0%)
-0.04
est: -0.03 (-32.6%)
-0.05
est: -0.04 (-10.7%)
-0.05
est: -0.05 (-0.3%)
-0.03
est: -0.04 (+14.6%)
-0.05
est: -0.05 (-9.0%)
-0.04
est: -0.05 (+24.5%)
-0.05
est: -0.04 (-16.0%)
-0.04
est: -0.03 (-17.0%)
-0.04
est: -0.04 (-2.9%)
-0.05
-0.07 – -0.03
-10.8% YoY
-0.02
-0.06 – -0.01
+45.4% YoY
-0.05
-0.15 – -0.01
-97.9% YoY
-0.02
-0.02 – -0.02
+59.8% YoY
0.05
0.05 – 0.05
+335.0% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 C 2/5 3/5 1/5 1/5 4/5 1/5 1/5
2026-05-28 C 2/5 3/5 1/5 1/5 4/5 1/5 1/5
2026-05-27 C 2/5 3/5 1/5 1/5 4/5 1/5 1/5
2026-05-26 C 2/5 3/5 1/5 1/5 4/5 1/5 1/5
2026-05-25 C 2/5 3/5 1/5 1/5 3/5 1/5 1/5
2026-05-22 C 2/5 3/5 1/5 1/5 3/5 1/5 1/5
2026-05-21 C 2/5 3/5 1/5 1/5 3/5 1/5 1/5
2026-05-20 C 2/5 3/5 1/5 1/5 3/5 1/5 1/5
2026-05-19 C 2/5 3/5 1/5 1/5 3/5 1/5 1/5
2026-05-18 C 2/5 3/5 1/5 1/5 3/5 1/5 1/5
2026-05-15 C 2/5 3/5 1/5 1/5 3/5 1/5 1/5
2026-05-14 C 2/5 3/5 1/5 1/5 3/5 1/5 1/5
2026-05-13 C- 1/5 2/5 1/5 1/5 3/5 1/5 1/5
2026-05-12 C- 1/5 2/5 1/5 1/5 3/5 1/5 1/5
2026-05-11 C- 1/5 2/5 1/5 1/5 3/5 1/5 1/5
2026-05-08 C- 1/5 2/5 1/5 1/5 3/5 1/5 1/5
2026-05-07 C- 1/5 2/5 1/5 1/5 3/5 1/5 1/5
2026-05-06 C- 1/5 2/5 1/5 1/5 3/5 1/5 1/5
2026-05-05 C- 1/5 2/5 1/5 1/5 3/5 1/5 1/5
2026-05-04 C- 1/5 2/5 1/5 1/5 3/5 1/5 1/5
2026-05-01 C- 1/5 2/5 1/5 1/5 3/5 1/5 1/5
2026-04-30 C- 1/5 2/5 1/5 1/5 3/5 1/5 1/5
2026-04-29 C- 1/5 2/5 1/5 1/5 3/5 1/5 1/5
2026-04-28 C- 1/5 2/5 1/5 1/5 3/5 1/5 1/5
2026-04-27 C- 1/5 2/5 1/5 1/5 3/5 1/5 1/5
2026-04-24 C- 1/5 3/5 1/5 1/5 2/5 1/5 1/5
2026-04-23 C- 1/5 3/5 1/5 1/5 2/5 1/5 1/5
2026-04-22 C- 1/5 3/5 1/5 1/5 2/5 1/5 1/5
2026-04-21 C- 1/5 3/5 1/5 1/5 2/5 1/5 1/5
2026-04-20 C- 1/5 3/5 1/5 1/5 2/5 1/5 1/5
2026-04-17 C- 1/5 3/5 1/5 1/5 2/5 1/5 1/5
2026-04-16 C- 1/5 3/5 1/5 1/5 2/5 1/5 1/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-97.84M
OE per share TTM
-0.07
Owner's Yield
-125.51%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
11.0%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 3 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 iShares S&P/ASX Small Ordinaries ETF ISO.AX 0.03% 22.5K 0.55%
2 Vanguard Australian Shares Index ETF VAS.AX 0.00% 494.8K 0.07%
3 Avantis International Small Cap Equity ETF AVDS 0.00% 214.10 0.30%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
-11.4K
Shares Outstanding
1.47B

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Marc Voigt Chief Executive Officer, MD, Chief Financial Officer, Chief Business Officer & Executive Director 849.6K male
Stephan Winckels Chief Medical Officer 756.3K male
Frederic Triebel Chief Scientific Officer & Executive Director 702.2K —
Deanne Miller Chief Operating Officer, General Counsel & Joint Company Secretary 518.0K female
Christian Mueller Chief Development Officer 389.5K male
Indira Naidu Joint Company Secretary — female
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Biotechnology